Is ARGX a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The bull case for ARGX (ARGX) rests on Vyvgart franchise momentum: Vyvgart posted its 17th consecutive quarter of growth in Q1 2026, with sales near $1.3 billion (up 63% year over year) and roughly 19,000 patients on treatment. Revenue (2025 product net sales) is ~$4.15B. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: argenx revenue is heavily concentrated in one molecule, efgartigimod, so any safety signal, pricing pressure, or slowdown in gMG and CIDP uptake would weigh directly on the whole company. Whether ARGX is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
argenx SE is a Netherlands-based, globally operating immunology company that trades in the US as a Nasdaq ADR. Its lead product, Vyvgart and the subcutaneous Vyvgart Hytrulo (efgartigimod), is an FcRn blocker that lowers pathogenic IgG antibodies. It is approved for generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), plus primary immune thrombocytopenia in Japan, and reached roughly 19,000 patients on treatment by the end of 2025. The investment picture is a classic biotech growth profile: revenue is compounding quickly (about $4.15 billion in 2025 global product net sales, up roughly 90% year over year, with Q1 2026 sales near $1.3 billion), the company turned profitable and holds a large cash cushion, and the pipeline aims to expand efgartigimod into new autoimmune indications while advancing next-generation FcRn and complement candidates. Against that, the market cap of roughly $47 billion prices in substantial future success, so the shares carry the volatility typical of a single-franchise-led biotech.
What's the case for buying ARGX?
1. Vyvgart franchise momentum
Vyvgart posted its 17th consecutive quarter of growth in Q1 2026, with sales near $1.3 billion (up 63% year over year) and roughly 19,000 patients on treatment. Uptake of the subcutaneous Hytrulo formulation and continued gMG and CIDP adoption are the core revenue engine. Each new label and geography adds to a still-expanding addressable base.
2. Label and indication expansion
argenx is pursuing efgartigimod in seronegative gMG, ocular myasthenia gravis, primary ITP, Graves' disease, myositis, and Sjogren's disease. A widening set of approved uses could turn a single molecule into a multi-indication franchise. Regulatory decisions and Phase 3 readouts across 2026 are the near-term swing factors.
3. Deep autoimmune pipeline
Beyond efgartigimod, argenx is advancing next-generation FcRn candidates (such as ARGX-213 and ARGX-124) and first-in-class assets including empasiprubart (a C2 complement inhibitor) and adimanebart. Its Vision 2030 framework targets 10 labeled indications and five pipeline candidates in Phase 3. This breadth is what supports the long-duration growth narrative.
4. Profitability and balance sheet
argenx has crossed into sustained profitability, reporting Q1 2026 profit of about $366 million (up 116% year over year) and adjusted EPS of $5.52. It held roughly $4.9 billion in cash and current financial assets at quarter end. That cushion funds pipeline investment without near-term dependence on capital markets.
What are the risks to ARGX?
argenx revenue is heavily concentrated in one molecule, efgartigimod, so any safety signal, pricing pressure, or slowdown in gMG and CIDP uptake would weigh directly on the whole company. The FcRn field is crowding: UCB (rozanolixizumab, zilucoplan), Johnson & Johnson (nipocalimab), and Immunovant (batoclimab and IMVT-1402) are all competing in overlapping indications, and AstraZeneca's complement inhibitors address parts of the same market. Pipeline setbacks or missed Phase 3 readouts could sharply reset expectations given the high valuation. As an ADR of a European company, holders also carry currency and cross-listing considerations. Biotech shares like ARGX tend to be volatile around clinical and regulatory events.
How is ARGX valued? (as of May 2026)
Snapshot for ARGX as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (2025 product net sales): ~$4.15B
- Revenue growth (2025 YoY): ~90%
- Q1 2026 net sales: ~$1.3B (+63% YoY)
- Q1 2026 profit: ~$366M
- Cash and current financial assets: ~$4.9B
- Market cap: ~$47B
argenx trades as a high-growth, richly valued biotech rather than on trailing earnings multiples, with the roughly $47 billion market cap reflecting expectations for continued Vyvgart expansion and pipeline success. The company is now profitable and self-funding, a meaningful shift from the cash-burning profile common to development-stage biotech. Figures are approximate and reflect data available around May 2026.
How do you decide if ARGX is a buy?
Rather than asking whether ARGX is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold ARGX indirectly through an index or sector ETF before adding more.
For the full picture, see the ARGX stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about ARGX against your real portfolio and see your actual exposure before deciding.
The bottom line on ARGX
The bottom line: ARGX's story right now is Vyvgart franchise momentum, with revenue (2025 product net sales) at ~$4.15B. If you believe that narrative continues, the call is about sizing ARGX sensibly and checking overlap with what you own; if you doubt it (the risk: argenx revenue is heavily concentrated in one molecule, efgartigimod, so any safety signal, pricing pressure, or slowdown in gMG and CIDP uptake would weigh directly on the whole company.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around ARGX with Walnut
Use ARGX as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is ARGX a good stock to buy right now?
+
The case for ARGX right now is Vyvgart franchise momentum, with revenue (2025 product net sales) at ~$4.15B. If you believe that thesis holds, ARGX is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is argenx revenue is heavily concentrated in one molecule, efgartigimod, so any safety signal, pricing pressure, or slowdown in gMG and CIDP uptake would weigh directly on the whole company. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does ARGX do?
+
argenx SE is a Netherlands-based, globally operating immunology company that trades in the US as a Nasdaq ADR.
What are the main risks of ARGX?
+
argenx revenue is heavily concentrated in one molecule, efgartigimod, so any safety signal, pricing pressure, or slowdown in gMG and CIDP uptake would weigh directly on the whole company. The FcRn field is crowding: UCB (rozanolixizumab, zilucoplan), Johnson & Johnson (nipocalimab), and Immunovant (batoclimab and IMVT-1402) are all competing in overlapping indications, and AstraZeneca's complement inhibitors address parts of the same market. Pipeline setbacks or missed Phase 3 readouts could sharply reset expectations given the high valuation. As an ADR of a European company, holders also carry currency and cross-listing considerations. Biotech shares like ARGX tend to be volatile around clinical and regulatory events.
What does argenx do?
+
argenx is an immunology company focused on autoimmune diseases. Its lead product, Vyvgart (efgartigimod), is an FcRn blocker that lowers harmful IgG antibodies, and it is approved for conditions including generalized myasthenia gravis and CIDP.
What is Vyvgart and why does it matter to ARGX?
+
Vyvgart, and its subcutaneous version Vyvgart Hytrulo, is efgartigimod, the drug behind nearly all of argenx's revenue. Its adoption in myasthenia gravis and CIDP drove roughly $4.15 billion in 2025 net sales, so Vyvgart uptake is the primary driver of the stock.
Is ARGX profitable?
+
Yes. argenx reported profit of about $366 million in the first quarter of 2026, up around 116% year over year, and held roughly $4.9 billion in cash and current financial assets. That marks a shift from the cash-burning profile typical of development-stage biotech.
How fast is argenx growing?
+
Growth has been rapid. Global product net sales rose about 90% year over year in 2025 to roughly $4.15 billion, and Q1 2026 sales of about $1.3 billion were up 63% from a year earlier, marking the 17th consecutive quarter of Vyvgart growth.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell ARGX; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.